THANKTIVA THANKTASTIC ANKTIVA
Live / Applied — First extension granted (statement of use) (as of 11 Dec 2025)
What this means for you
Not registered yet, but its 19 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98456624
- Mark type
- Stylized text
- Filed
- 19 Mar 2024
- Published for opposition
- 06 May 2025
- Attorney of record
- Alicia M. Passerin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical preparations and substances for the prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; biological preparations for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases and infectious diseases in the fields of immunotherapy and immuno-oncology; anti-infectives for medical use for the treatment and prevention of immunologic dysfunction, autoimmune diseases and infectious diseases
- Class 042 — Scientific and technological services: Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases
- Class 044 — Medical, beauty and agricultural services: Medical services; medical information; providing a website featuring medical information in the fields of pharmaceuticals, immunotherapy, immuno-oncology, cancer, autoimmune diseases, and infectious diseases; providing medical information relating to pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases
Owner
- ImmunityBio, Inc., San Diego, CA, US
- ImmunityBio, Inc., San Diego, CA, US
Prosecution history
- 12 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Dec 2025 — SOU EXTENSION 1 GRANTED
- 11 Dec 2025 — SOU EXTENSION 1 FILED
- 11 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 06 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 May 2025 — PUBLISHED FOR OPPOSITION
- 30 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 01 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 01 Apr 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 30 Dec 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 30 Dec 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 03 Oct 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED